The activation of nuclear factor kB (NFkB) is a key event in immune and inflammatory responses. In this study, a cellpenetrating transport peptide, transportan (TP) or its shorter analogue TP 10, was used to facilitate the cellular uptake of an NFkB decoy. Peptide nucleic acid (PNA) hexamer or nonamer was linked to the transport peptide by a disulfide bond. NFkB decoy oligonucleotide consisted of a doublestranded consensus sequence corresponding to the kB site localized in the IL-6 gene promoter, 5
Introduction
The nuclear factor kB (NFkB) transcription factor is part of the NFkB/Rel protein family and has been shown to regulate the expression of genes involved in immune and inflammatory responses. 1, 2 NFkB has been found to be activated in many cell types in response to a wide variety of stimuli. In unstimulated cells, NFkB is localized in the cytoplasm as an inactive complex composed of a transcriptionally active dimer associated with the inhibitory protein IkB. 3 Upon stimulation, IkB becomes phosphorylated and degraded, unmasking the nuclear localization signal of NFkB. This will permit the active transcription factor to translocate to the nucleus, bind to the kB DNA motifs and activate target genes. 1, [4] [5] [6] There are many activators of NFkB, such as proinflammatory cytokines (eg IL-1, TNFa), phorbol esters, growth factors, oxidizing agents and bacterial or viral products. 1, 5, 7 The signal transduction pathways that lead to the activation of NFkB have not been fully clarified. Activation of NFkB induced by cytokines involves the proteolytic degradation of IkB initiated by two IkB kinases, IKK1 and IKK2. 8, 9 Several upstream activators of IKK activity have been identified. Binding of the proinflammatory cytokine interleukin-1b (IL-1b) to its receptor has been shown to induce the association of the IL-1 receptor accessory protein, the adapter protein MyD88 and the IL-1 receptor-associated kinase, leading to the activation of TRAF-6. 10 In turn, TRAF-6 activates the TAK1 kinase that will activate NFkB-inducing kinase, which ultimately induces IKK activation, leading to the phosphorylation and degradation of IkB with subsequent release of NFkB. 11 NFkB, in turn, may induce IL-1b expression, leading to a positive autoregulatory loop, with a prolonged inflammatory reaction as a result. The IL-1-induced activation of NFkB also regulates the expression of other proinflammatory cytokines. One of the NFkB target genes encodes the cytokine interleukin-6 (IL-6). [12] [13] [14] As an early and immediate transcriptional activator of genes encoding inflammatory cytokines, NFkB might be a suitable drug target for diseases like rheumatoid arthritis, bronchial asthma, septic shock and Alzheimer's disease (AD) or other neurodegenerative conditions, where application of NFkB inhibitors might prevent upregulation of inflammatory components observed in these diseases.
Several strategies to control NFkB activation and the subsequent downstream activating cascade have been used, such as steroid hormones, antioxidants, specific protease inhibitors, IkB transdominant mutants, and synthetic antisense oligonucleotides to inhibit selectively the expression of a particular gene product of NFkB/Rel family or of NFkB target genes. [15] [16] [17] [18] In addition, synthetic double-stranded DNA (dsDNA) with high affinity for NFkB, NFkB decoy, have been shown to block the induction of gene expression mediated by NFkB in vitro 15, [19] [20] [21] [22] and in vivo. 23, 24 With the use of decoy oligonucleotides, the function of a particular DNA-binding protein or protein complex can be inhibited since the decoy competes for protein binding with the authentic binding elements, interfering with gene regulation. This may be a useful method for the treatment of a wide spectrum of human diseases (cf. Morishita et al, 24 Ono et al, 25 Sharma et al, 26 Suzuki et al, 27 Vos et al.
28
). However, one of the problems with the transcription factor decoy strategy is that the uptake of DNA into mammalian cells is not very efficient, and therefore high concentrations and long incubation times have to be used to obtain significant effects.
Previously, peptides such as penetratin and transportan (TP) have been shown to penetrate cell membranes. 29, 30 These peptides may also be used as transport peptides to facilitate translocation of other molecules, such as peptide nucleic acid (PNA), across biological membranes. 31 In this study, we have used the cellpenetrating peptides, TP and its N-terminally truncated analogue transportan 10 (TP10), to increase the cellular uptake of oligonucleotide transcription factor decoy. TP is a 27 amino-acid-long peptide (galanin (1-12)-Lysmastoparan (1-14) amide). Both TP and TP10 have earlier been shown to be able to translocate covalently bound larger molecules across the plasma membrane in an energy-and receptor-independent manner. 30 TP or TP10 was linked by a disulfide bond to a cysteineextended PNA hexamer (PNA(6)) or nonamer (PNA(9)) molecule. PNA is a nucleic acid analogue consisting of an achiral polyamide backbone that has been shown to form stable and tight complexes with complementary DNA or RNA. 32, 33 The PNA/DNA binding is 10-100 times stronger than DNA/DNA, a feature that can be used to form specific complexes of transport peptide-PNA and the oligonucleotide transcription factor decoy. After uptake, the disulfide bond is reduced in the cytoplasm, leading to the rapid dissociation of the PNA from the carrier peptide, 34 permitting PNA-NFkB decoy to associate with the NFkB/Rel transcription factor in the cytoplasm, or transport peptide-PNA-NFkB decoy may translocate to the nucleus and associate with the activated translocated NFkB transcription factor dimer ( Figure 1 ). The stability of the transport peptide-PNA-NFkB decoy complex and the effect on IL-1-induced NFkB activation and subsequent induction of IL-6 expression was investigated in rat Rinm5F insulinoma cells.
Results
Transport peptide linked to nonamer PNA formed stable complexes with oligonucleotide NFkB decoy A Cys-PNA hexamer or nonamer were synthesized and coupled to the cell penetrating peptide TP or its analogue TP10 via a disulfide bridge. A ds oligonucleotide (ds DNA) containing a consensus sequence for NFkB binding (NFkB decoy) and a single-stranded 3 0 -terminal Figure 1 Proposed effect of the transport peptide-PNA-NFkB decoy complexes on IL-1-mediated induction of IL-6 expression. The ds oligonucleotide contains a consensus sequence for NFkB binding and a protruding single-stranded 3 0 -terminal complementary to PNA coupled to a transport peptide (ie TP or TP10). The uptake of the transport peptide-PNA-NFkB decoy complex into the cell is illustrated. Inside the cell, the NFkB will bind to the decoy, thereby blocking the binding of NFkB to response elements present in the IL-6 promoter and inhibit induction of IL-6 transcription.
Cellular delivery of NFjB decoy L Fisher et al sequence complementary to the PNA sequence was hybridized to the transport peptide PNA construct (transport peptide-PNA-NFkB decoy, Figure 2 ). This transport peptide-PNA-NFkB decoy complex was used to mimic the kB consensus sequence for NFkB binding and to inhibit the effect of activation of NFkB upon IL-1b stimulation, and thereby also to inhibit the downstream activation of transcription of cytokine genes, for example, the NFkB-mediated induction of IL-6 gene expression.
The stability of the different transport peptide-PNAoligonucleotide complexes was investigated. 32 P-labeled oligonucleotides were incubated in the presence of different transport peptide-PNA constructs (Figure 3) . The complexes were separated from radioactively labeled unbound oligonucleotides by polyacrylamide gel electrophoresis. TP linked to PNA(9) formed more stable complexes with the 32 P-labeled ds oligonucleotide than transport peptide linked to the shorter PNA(6) both at room temperature and at 371C. No 32 P-labeled oligonucleotide dissociation from TP-PNA could be detected with the TP-PNA(9)-oligonucleotide complex, whereas with the PNA(6) oligonucleotide not bound to the TP-PNA construct could be detected.
Low concentrations of transport peptide-PNA-NFkB decoy complexes inhibited the IL-1b-induced NFkB-binding activity
The effect of IL-1b on NFkB-binding activity in nuclear extracts from Rinm5F cells was investigated by electrophoretic mobility shift assay (EMSA). Incubation with IL-1b (10 ng/ml) for 30 min induced the binding of DNA-binding complexes to radiolabeled specific kB oligonucleotides as shown by the strong mobility shifted band observed on the EMSA gel (Figure 4a ). Using an excess of unlabeled specific kB oligonucleotide, the band observed was totally competed away, indicating that this band corresponds to specific binding. Furthermore, supershift analysis using antibodies against NFkB subunit p65 demonstrated that the bands correspond to NFkB (Figure 5b ). No detectable binding activity was found in untreated Rinm5F cells ( Figure  4b ), indicating that, like in the majority of other cells or cell lines, NFkB is an inducible transcription factor.
The effect of the different complexes of transport peptide-PNA-NFkB decoy on IL-1b-induced activation of NFkB-binding activity was also investigated by EMSA. After preincubation of the cells for 1 h with TP-PNA(6)-NFkB decoy, TP-PNA(9)-NFkB decoy, TP10-PNA(6)-NFkB decoy and TP10-PNA(9)-NFkB decoy (1 mM), the IL-1b-(10 ng/ml) induced activation of NFkB-binding activity was significantly reduced ( Figure  4b ). The results show that the shorter PNA hexamer together with either TP or TP10 does not block the NFkB-binding activity as efficient as the longer PNA nonamer, where the NFkB-binding activity is almost completely blocked (Figure 4b and c). A 1 h preincubation with NFkB decoy (1 mM) alone could not block the NFkB-binding activity as shown by the presence of the specific band in the EMSA (Figure 4c ). Longer preincubation with NFkB decoy (1 mM), for up to 48 h, was not sufficient to block the NFkB-binding activity significantly (approx. 10% nonsignificant decrease compared to IL-1b treatment in the absence of NFkB decoy). Similarly, nuclear extract from cells preincubated with a transport peptide-PNA-scrambled oligonucleotide Figure 2 Schematic illustration of the transport peptide-PNA-NFkB decoy and transport peptide-PNA-NFkB decoy scrambled complexes used in the study. The ds oligonucleotide contains a consensus sequence for NFkB binding (in bold), with a protruding single-stranded 3 0 -terminal complementary to PNA coupled to a transport peptide (ie TP or TP10). The sequence for PNA (9) is shown. The sequence for PNA (6) , also used in this study, is ACACAA. The high-molecular-weight bands corresponds to the transport peptide-PNA-NFkB decoy complex (TP-PNA ds*) and the lower-molecularweight bands corresponds to ds* oligonucleotides.
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showed a strong NFkB-binding activity after IL-1b treatment, as observed by the appearance of the specific band in the EMSA (Figure 4d ). This indicates that scrambled oligonucleotide sequence did not bind the NFkB dimer. No detectable binding activity was found in cells treated with NFkB decoy, TP or scrambled NFkB decoy, demonstrating that they did not have any effect on the NFkB-binding activity per se (Figure 4d ). The specificity of the effect was further demonstrated by EMSA using an AP-1 probe, which was unaffected by the NFkB decoy treatment ( Figure 5 ). We found a dosedependent effect of TP-PNA(9)-NFkB decoy on NFkBbinding activity ( Figure 6 ). A measure of 0.7 mM of the TP-PNA(9)-NFkB decoy was estimated to result in a 50% inhibition of the NFkB-binding activity. At 1 mM, the concentration used in all our experiments, the inhibition was estimated to 6373% compared to NFkB decoy alone where no significant inhibition could be detected (2.471.2%).
Transport peptide-PNA-NFkB decoy complexes significantly decreased the IL-1b-induced IL-6 mRNA expression
The expression levels of IL-6 were analyzed to investigate if the transport peptide-PNA-NFkB decoy complex could block NFkB downstream effects. Stimulation of the insulinoma Rinm5F cells by IL-1b (10 ng/ml, 2 h) resulted in increased mRNA levels of the proinflammatory cytokine IL-6 as determined by semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR) ( Figure 7) . Preincubation of the cells with TP-PNA(9)-NFkB decoy (1 mM, 60 min) significantly decreased the induction of the IL-6 mRNA transcript (2073% reduction compared to IL-1b-treated cells). In contrast and as expected, preincubation with TP-PNA(9)-scrambled oligonucleotide or NFkB alone had no effect on IL-1b-induced IL-6 expression. Cells treated with 1 mM NFkB decoy alone for 48 h did not show a decrease in IL-6 
Discussion
In the present study, we have shown that IL-1b-induced NFkB activation in rat Rinm5F insulinoma cells, with subsequent induction of IL-6 mRNA expression. The IL1b-induced NFkB activation could be significantly blocked by the TP-PNA(9)-NFkB decoy complex (1 mM). This is the first example of a noncovalent binding of a cargo to a transport peptide using PNA as a linker. The complex including the shorter PNA(6) did not block the IL-1b-induced NFkB activation to the same extent under the same conditions (approx. 30% compared to 60% with PNA (9)). In the absence of transport peptide-PNA construct, no significant effect of the NFkB decoy on IL-1b-induced NFkB activation could be observed.
We also observed that TP linked to PNA(9) formed more stable complexes with the 32 P-labeled ds oligonucleotide than TP linked to PNA (6) . These results are in accordance with the calculated melting temperature for the PNA/DNA complexes. Two different methods for calculation of T m for PNA(9)/DNA and PNA(6)/DNA at 1 mM concentration were used. First, using PNA designer calculator at Applied Biosystems homepage (http:/ / www.appliedbiosystems.com/support/pnadesigner.cfm) T m of 59 and 331C were obtained for PNA(9)/DNA and for PNA(6)/DNA, respectively. Calculations by the method described by Griffin and Smith 35 resulted in T m of 52 and 291C for PNA(9)/DNA and PNA(6)/DNA, respectively. From these results, it can be concluded that the PNA(9)/DNA melting temperature is much higher than for the hexamer duplex, and that in our experimental conditions (371C) the equilibrium between duplex and unpaired single strands should be shifted towards to the single strands if PNA(6) is used.
Our results showed that the increased IL-6 production induced by IL-1b was, in part, due to increased activity of NFkB, since blocking the NFkB activation by approx. 60% also led to a significantly reduced IL-1b-induced IL-6 expression. Binding of the NFkB decoy to the NFkB dimer consequently reduced the binding of NFkB to the promoter region of the IL-6 gene and resulted in an alteration in the IL-6 mRNA expression. A total blockage of the induction of the IL-6 mRNA expression could not be expected, since the TP-PNA(9)-NFkB decoy complex (1 mM) did not completely block the IL-1b-induced NFkBbinding activity. Furthermore, IL-6 expression is not exclusively regulated through an NFkB-dependent pathway. The IL-6 gene promoter contains binding sites for other transcription factors than NFkB, including AP-1, MRE and NF-IL6 transcription factors. [36] [37] [38] [39] Both AP-1 and NF-IL6 have been shown to be involved in the regulation of IL-1b-induced IL-6 expression. 36, 37, 40 However, NFkB has been considered to be the predominant transcription factor regulating the IL-6 gene in response to inflammatory stimuli.
5,41
Figure 5 Representative EMSA showing a specific effect on NFkBbinding activity. (a) Cells were preincubated for 1 h at 371C with TP10-PNA(9)-NFkB decoy (lanes 4 and 5) or NFkB decoy (lanes 6 and 7) followed by 30 min incubation with 10 ng/ml IL-1b (lanes 2-7). The AP-1 probe are shown for comparison to demonstrate that the effect was specific for NFkB-binding activity. (b) Supershift analysis of nuclear extracts from cells incubated with 10 ng/ml IL-1b (lanes [1] [2] [3] [4] [5] showing the specificity of the band using antibodies against NFkB subunit p65 (lanes 3-5). 
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We have used the rat insulinoma cell line Rinm5F as a model system to investigate the NFkB decoy approach to block IL-1b-induced NFkB activation and NFkB downstream effects. The rat insulinoma cell line Rinm5F has often been used as a model in the study of IL-1 effects, since they have a high density of IL-1 receptors. 42, 43 The NFkB decoy approach can further be applied on other types of cells. The importance of NFkB in regulating IL-6 gene expression in primary glial cells has also been suggested by Ye and Johnson, 22 based on a study where cells were pretreated with NFkB decoy. In their study, an approx. 60% inhibition of IL-1b-induced IL-6 expression was observed. However, to obtain this effect of the decoy on IL-1b-induced NFkB activation and IL-6 expression, a preincubation with 25 mM of the oligonucleotide for 24 h had to be used. In another study, 15 the NFkB decoy approach was used to inhibit the LPS-induced IL-6 secretion in primary splenocytes. A 30 and 49% decrease in IL-6 production was observed after treatment with 2 mM decoy for 24 and 72 h, respectively. The requirements for long incubation times and high concentrations to obtain significant effects are due to the fact that the uptake of DNA into mammalian cells is not very efficient. Our work shows that the uptake of the ds oligonucleotides is greatly improved using the transport peptide, TP, linked to PNA. It was possible to block significantly the NFkB activation and its down stream effects after only 1 h preincubation at as low concentrations as 1 mM.
Compelling evidence exists showing that inflammatory processes are involved in the pathology of neurodegenerative diseases like AD. [44] [45] [46] [47] The transcription factor NFkB has been shown to play a role in AD. Activated NFkB has been shown to be overexpressed in AD brain, [48] [49] [50] which may lead to the elevated levels of IL-6 expression observed in neurodegenerative disorders like AD. 45, 51, 52 Increased levels of IL-6 have been reported to be present in the early stage of the amyloid-b plaque formation in AD, 53 making the assumption that IL-6 may even be an early primer for neuropathological changes that occur in AD. Therefore, a tight regulation of the IL-6 gene in the brain may be important for the control of inflammatory processes seen in AD. Since we and others have shown that IL-1b-induced IL-6 expression is regulated at least in part by NFkB, methods to block this transcription factor may be useful to suppress the IL1b-induced IL-6 expression. Activated NFkB in response to inflammatory stimuli may also generate a positive autoregulatory loop, since some of the NFkB-induced proteins, like IL-1b, are also activators of NFkB. If NFkB activity remains high, inflammatory mediators are continuously being synthesized and the inflammatory reaction will be prolonged, leading to pathology. It is possible that NFkB, as an abundant transcription factor in the brain, becomes inappropriately activated in diseases like AD, thereby causing the increased expression of proinflammatory genes. One problem in blocking the NFkB activation is the fact that NFkB has also been shown to have protective effects in neurons. [54] [55] [56] Therefore, therapies aimed at lowering the NFkB activity should distinguish between the NFkB complexes in neurons and other cell types like glial cells, the main producers of proinflammatory cytokines. Moerman et al 56 reported that the predominant kB-binding factor in neurons was distinct from the bona fide NFkB, that is, the p65-p50 heterodimer, which is the most important NFkB complex in the inflammatory response. Since the NFkB complexes have different DNA-binding specificities (cf. Moerman et al, 57 Kunsch et al, 58 Schmid et al, 59 Toledano et al 60 ) it may be possible to design an NFkB decoy that blocks the effect of NFkB in glial cells but not in neuronal cells.
In conclusion, inhibition of specific transcriptional regulatory proteins may be a useful tool for determining their roles in cellular differentiation and development, in immunoregulatory processes, stress conditions, inflammation, neuroprotection and neurodegenerative conditions. In addition, it may provide a potential new therapeutic strategy to reduce or inhibit the expression of proteins involved in the pathogenesis of chronic diseases. A great potential exists in the capacity of the transport peptide-PNA oligonucleotide complexes to modulate the expression of proteins regulated by, for example, NFkB. Furthermore, the design of the complexes with an oligonucleotide decoy with a protruding single-stranded 3 0 -terminal complementary to the PNA sequence permits the use of the same TP-PNA construct in combination with decoy containing other consensus sequences.
Materials and methods

Synthesis of peptides and PNA constructs
The peptides (TP: GWTLNSAGYLLG 13 KINLKALAA LAKKIL amide; TP10: AGYLLG 7 KINLKALAALAKKIL amide) were synthesized in a stepwise manner on an Applied Biosystem Model 431A peptide synthesizer using t-Boc strategy of solid phase peptide synthesis Figure 7 Effect of NFkB transcription factor decoy on IL-1b-induced IL-6 expression in rat Rinm5F cells in the presence or absence of TP-PNA. Cells were preincubated for 1 h with 1 mM NFkB decoy7TP-PNA(9) or TP-PNA(9)-scrambled NFkB oligonucleotide followed by 2 h treatment with 10 ng/ml IL-1b. RNA was isolated, reversed transcribed to cDNA and then analyzed for IL-6 transcripts using PCR. Cellular delivery of NFjB decoy L Fisher et al according to the protocol described. 61 t-Boc-Cys(Npys) was manually coupled to the e-amino group on 13 K in TP and on 7 K in TP10. Cys-PNA oligomers 6-(Cys-ACACAA) or 9-mer (Cys-ACACAAGGA)) were synthesized manually as described by Egholm et al 62 by using t-Boc strategy. The purity of peptides and PNA oligomers was 498% as demonstrated by HPLC on an analytical Nucleosil 120-3 C 18 reverse phase HPLC column (0.4 cm Â 10 cm).
The constructs were synthesized by dissolving 1 eq. of peptide-Cys(Npys) and 1.2 eq. of free thiol Cys-PNA in deoxygenated DMSO/DMF mixture (eg 3/2 (v/v)). The mixture was stirred gently overnight under nitrogen gas. Purification of the constructs was performed on Gynkotek HPLC (Munich, Germany) with Nucleosil 120-3 C 18 reverse phase HPLC column (3 cm Â 14 cm).
The molecular masses of the peptides, Cys-PNA and constructs were determined by MALDI-TOF mass spectrometry (Voyager DE STR, Applied Biosystem) and the calculated values were obtained in each case.
Binding study of transport peptide-PNA constructs to ds oligonucleotides Single-stranded NFkB oligonucleotide (5 0 -AGTTGAGGG GACTTTCCCAGGC-3 0 ) was 5 0 -end labeled with [g-32 P]dATP using T4 polynucleotide kinase, and then annealed to its complementary strand (5 0 -GCCTGGGAAAGTCCCCT CAACTTCCTTGTGT-3 0 ). Unincorporated nucleotides were separated from the labeled oligonucleotides using a Chromaspin-10 column (Clontech, USA). The ds labeled oligonucleotides were annealed to the complementary PNA sequence (6-(ACACAA) or 9-mer (ACA CAAGGA)) linked to TP or TP10 in a 1:1 mixture. The mixture was incubated at 371C for 1 h decreasing the temperature to room temperature for the next hour or in room temperature for 2 h. The stability of the different transport peptide-PNA oligonucleotide constructs was analyzed by electrophoresis on a 12% polyacrylamide gel in 0.5 Â TBE buffer (90 mM Tris base, 90 mM boric acid, 2 mM EDTA (pH 8.3)). The gels were exposed to a phosphor imager screen (Molecular dynamics; Amersham Biosciences, Sweden) for 24 h.
Cell culture and treatment
Rat Rinm5F insulinoma cells were grown in RPMI 1640 medium supplemented with 5% (v/v) fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin (Invitrogene, Scotland). The cells were cultured at 5 Â 10 4 cells/cm 2 in 10 and 21 cm 2 culture dishes for RT-PCR and for EMSA analysis, respectively. The cultures were maintained for 3 days at 371C in a humified atmosphere of 5% (v/v) CO 2 in air.
At 1 day prior to the experiments, the culture medium was substituted to serum-free RPMI 1640 medium containing 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin, supplemented with 5 mg/ml insulin, 5 mg/ml transferrin, 30 nM sodium selenite, 100 mM putresceine and 20 nM progesterone. The Rinm5F cells were treated with different complexes of transport peptide-PNA-NFkB decoy or transport peptide-PNA-scrambled (5 0 -GCCTGTCGACGACGACT CAACTTCCTTGTGT-3 0 ) oligonucleotides or NFkB decoy alone. The ds oligonucleotides were allowed to anneal to the complementary PNA sequence linked to transportan (100 mM:100 mM ratio) by letting the mixture incubate for 1 h at 371C, and then the temperature was slowly decreased from 371C to room temperature during 1 h. The constructs were used immediately after annealing, adding them directly to the culture medium (final concentration 1 mM). After 1 h incubation, rat recombinant IL-1b (10 ng/ml) was added for 30 min for the analysis of NFkB activity by EMSA or for 2 h for RT-PCR analysis of IL-6 mRNA expression. Cells treated with only IL-1b (10 ng/ml) were used as controls. Untreated cell cultures were treated with an equivalent volume of supplemented RPMI 1640 medium, cells were also treated with TP-PNA, NFkB decoy and scrambled oligonucleotides alone without the addition of IL-1b. All incubations were performed in serum-free supplemented RPMI 1640 medium at 371C.
Nuclear extract preparation and EMSA
The cell culture medium was removed and the cells washed in ice-cold phosphate buffered saline (PBS). The cells were then collected with a cell scraper in ice-cold PBS, centrifuged at 1500 rpm for 5 min at 41C and washed again in ice-cold PBS. The remaining steps of the nuclear extraction procedure were performed at 41C. Cells were resuspended in HB buffer containing 10 mM Tris pH 7.3, 10 mM KCl, 1.5 mM MgCl 2 , 0.5 mM PMSF, 0.5 mM b-mercaptoethanol and centrifuged for 25 s. The pellet was resuspended in lysis buffer (HB buffer containing 0.4% (v/v) Nonidet-40) and incubated on ice for 10 min. Nuclei were pelleted by centrifugation at full speed in a microfuge for 5 min. The nuclear pellets were thereafter lysed in 30 ml buffer C (20 mM HEPES pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM dithiothreitol (DTT), 1 mM PMSF) and rocked vigorously on a shaking platform for 30 min. The samples were centrifuged for 5 min and the supernatants containing the nuclear proteins were collected. The protein concentration of the samples was determined by Bradford assay (Bio-Rad Laboratories, USA).
The EMSA was performed by using the ds synthetic oligonucleotides mimicking the NFkB response element. To detect NFkB-binding activity, 10 mg total protein from the nuclear extracts were incubated for 30 min at room temperature with 1 Â 10 5 cpm of the 32 P end-labeled NFkB probe (kB consensus sequence 5 0 -AGTTGAGGG GACTTTCCCAGGC-3 0 ) or 32 P end-labeled AP-1 probe (5 0 -CGCTTGATGAGTCAGCCGGAA-3 0 ) to demonstrate that the effect of the NFkB decoy was specific for NFkBbinding activity. The binding buffer used was composed of 10 mM Tris pH 7.4, 50 mM NaCl, 1 mM EDTA, 6%(v/v) glycerol. As a nonspecific competitor, 2 mg of poly-dIdC was added to the binding reactions. Specificity of the shifted bands were demonstrated by competition using unlabeled ds NFkB probe in 100-fold excess and by supershift analysis, where nuclear extracts were incubated in room temperature for 30 min with an antibody against NFkB p65 subunit (Santa Cruz Biotechnology, Santa Cruz, CA, USA) prior to the addition of the other components of the reaction mixture. A negative control with no DNA-binding protein extract in the binding reaction was also included. Oligonucleotides with bound NFkB protein were separated from free oligonucleotides by electrophoresis on a 5% nondenaturing polyacrylamide gel in 0.5 Â TBE buffer. The gels were analyzed by 
Relative RT-PCR analysis
Total RNA was extracted immediately after homogenization in Ultraspect solution (Biotech laboratories Inc., USA) according to the manufacturer's instructions. Total RNA (1 mg) from each culture was reverse transcribed to cDNA for 1 h at 371C in a reaction mixture (50 ml) containing 200 U M-MLV reverse transcriptase, 2 mM random primers, 0.5 mM dNTP, 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl 2 , 80 U RNase out and 10 mM DTT. A measure of 2 ml of the resulting cDNA was analyzed for DNA sequences encoding IL-6 using the PCR. The transcripts coding for 18S rRNA were used as an internal control with the 18S primers:competimer ratio of 1:6 (Ambion, Inc., USA). The sequences of the PCR primers were: IL-6 forward, 5 0 -AAGAAAGA CAAAGCCSAGAGTC-3 0 ; reverse, 5 0 -CACAAACTGA TATGCTTAGGC-3 0 . The PCR mix contained 2.5 U Taq polymerase, 1.5 mM MgCl 2 , 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 0.2 mM of each dNTP and 0.5 mM of the forward and reversed primers of IL-6 and primers for 18S. The cycling conditions were as follows: 951C for 1 min; 551C for 1 min and 721C for 1 min. Amplification consisted of 32 cycles and it was followed by an extension period of 10 min at 721C. After the final cycle, the samples were cooled at 41C. The specificity of the PCR primers used has previously been verified by sequencing of the obtained PCR products. 63 The obtained PCR products were separated on a 1.7% agarose gel using ethidiumbromide as staining. The gels were subjected to trans-UV illumination and photographed. The intensity of the ethidiumbromide-stained bands were quantified using the Image Gauge V3.46 programme (Fujifilm, Image Gauge V3.46).
